Next Article in Journal
SIOG (International Society of Geriatric Oncology) Recommendations for Anthracycline Use in the Elderly
Previous Article in Journal
Anthracyclines: A Cornerstone in the Management of Non-Hodgkin’s Lymphoma
 
 
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ongoing Trials in Low-Grade Lymphoma

by
Alexander Burchardt
Department of Hematology, Justus-Liebig University Hospital, Klinikstrasse 33, 35385 Giessen, Germany
Hematol. Rep. 2011, 3(s3), e5; https://doi.org/10.4081/hr.2011.s3.e5
Submission received: 25 July 2011 / Revised: 10 October 2011 / Accepted: 25 October 2011 / Published: 28 October 2011

Abstract

There are many therapies available for the management of low-grade lymphoma. With follicular lymphoma, for example, combination of chemotherapy and rituximab (immuno-chemo-therapy) and consecutive maintenance therapy for 2 years is the current standard of care. To date, the most widely used regimen seems to be rituximab combined with cyclo phosphamide, doxorubicin, vincristine, and prednisone (RCHOP). Substitution of liposomal doxorubicin in place of conventional doxorubicin may improve outcomes in this indication, although evidence for its use in low-grade lymphoma is not as relevant as in aggressive lymphoma. Bendamustine, in combination with rituximab, has shown very good efficacy and tolerability in several lymphoma types, particularly follicular lymphoma and other low-grade lymphomas. Other combinations, such as those including bortezomib and lenalidomide, are under investigation in low-grade lymphoma, and the duration of rituximab maintenance therapy following bendamustine−rituximab-containing induction is being researched by the German Study Group for Indolent Lymphoma (StiL).
Keywords: low-grade lymphoma; treatment; rituximab; non-pegylated liposomal doxorubicin; bendamustine low-grade lymphoma; treatment; rituximab; non-pegylated liposomal doxorubicin; bendamustine

Share and Cite

MDPI and ACS Style

Burchardt, A. Ongoing Trials in Low-Grade Lymphoma. Hematol. Rep. 2011, 3, e5. https://doi.org/10.4081/hr.2011.s3.e5

AMA Style

Burchardt A. Ongoing Trials in Low-Grade Lymphoma. Hematology Reports. 2011; 3(s3):e5. https://doi.org/10.4081/hr.2011.s3.e5

Chicago/Turabian Style

Burchardt, Alexander. 2011. "Ongoing Trials in Low-Grade Lymphoma" Hematology Reports 3, no. s3: e5. https://doi.org/10.4081/hr.2011.s3.e5

APA Style

Burchardt, A. (2011). Ongoing Trials in Low-Grade Lymphoma. Hematology Reports, 3(s3), e5. https://doi.org/10.4081/hr.2011.s3.e5

Article Metrics

Back to TopTop